It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
While the signaling pathways and transcription factors involved in the differentiation of thyroid follicular cells, both in embryonic and adult life, are increasingly well understood, the underlying mechanisms and potential crosstalk between the thyroid transcription factors Nkx2.1, Foxe1 and Pax8 and inductive signals remain unclear. Here, we focused on the transcription factor Sox9, which is expressed in Nkx2.1-positive embryonic thyroid precursor cells and is maintained from embryonic development to adulthood, but its function and control are unknown. We show that two of the main signals regulating thyroid differentiation, TSH and TGFβ, modulate Sox9 expression. Specifically, TSH stimulates the cAMP/PKA pathway to transcriptionally upregulate Sox9 mRNA and protein expression, a mechanism that is mediated by the binding of CREB to a CRE site within the Sox9 promoter. Contrastingly, TGFβ signals through Smad proteins to inhibit TSH-induced Sox9 transcription. Our data also reveal that Sox9 transcription is regulated by the thyroid transcription factors, particularly Pax8. Interestingly, Sox9 significantly increased the transcriptional activation of Pax8 and Foxe1 promoters and, consequently, their expression, but had no effect on Nkx2.1. Our study establishes the involvement of Sox9 in thyroid follicular cell differentiation and broadens our understanding of transcription factor regulation of thyroid function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Instituto de Investigaciones Biomédicas “Alberto Sols”. Consejo Superior de Investigaciones Científicas (CSIC) y Universidad Autónoma de Madrid (UAM), CSIC-UAM., Madrid, Spain (GRID:grid.466793.9) (ISNI:0000 0004 1803 1972); Unidad de Patología Neuromuscular, Servicio de Neuropediatría, Institut de Recerca Sant Joan de Déu, Laboratorio de Investigación Aplicada en Enfermedades Neuromusculares, Esplugues de Llobregat, Barcelona, Spain (GRID:grid.411160.3) (ISNI:0000 0001 0663 8628)
2 Instituto de Investigaciones Biomédicas “Alberto Sols”. Consejo Superior de Investigaciones Científicas (CSIC) y Universidad Autónoma de Madrid (UAM), CSIC-UAM., Madrid, Spain (GRID:grid.466793.9) (ISNI:0000 0004 1803 1972)
3 Instituto de Investigaciones Biomédicas “Alberto Sols”. Consejo Superior de Investigaciones Científicas (CSIC) y Universidad Autónoma de Madrid (UAM), CSIC-UAM., Madrid, Spain (GRID:grid.466793.9) (ISNI:0000 0004 1803 1972); Instituto de Salud Carlos III, Centro de Investigaciones Biomédicas en Red del Cáncer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
4 de Duve Institute and Université Catholique de Louvain, Cell Biology Unit, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)